SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Moxetumomab pasudotox

Cat. No.:	HY-P99255
CAS No.:	1020748-57-5
Target:	Antibody-Drug Conjugates (ADCs); CD22
Pathway:	Antibody-drug Conjugate/ADC Related; Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Moxetumomab pasudotox (CAT 8015) is anti-CD22 immunotoxin containing an anti-CD22 F_v and Pseudomonas exotoxin. CD22 is a cell surface receptor expressed on a variety of malignant B-cells. Moxetumomab pasudotox can be used in the research of hairy cell leukemia (HCL)[1][2][3].
In Vitro	Moxetumomab pasudotox (0-10 mg/mL, 66 h) reduces cell viability of BCP-ALL cells (determined by Annexin-V negative)[3]. The binding and internalization of MP/CD22 complexes is correlated with pre-B ALL cell line responses to MP[5]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Moxetumomab pasudotox (300 mg/kg, i.v., every other day) prolongs median survival in 697 cell model ($P < 0.0001$)[3]. Moxetumomab pasudotox (0.4 mg/kg, i.v. three doses, every other day) clears the bone marrow (BM) from acute lymphoblastic leukemia (ALL), but disease relapses from discrete BM-sites in NSG mouse model[4]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NSG (NOD.Cg-Prkdc^{scid} Il2rg^{tm1Wjl}/SzJ) mouse model[4]
Dosage:	0.4 mg/kg
Administration:	Intravenous injection (i.v.), three doses, every other day.
Result:	Survived much longer but died from ALL after 40 d. Reduced BM-infiltration to 4% on day 8.

REFERENCES

[1]. Kreitman RJ, et al. Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. J Hematol Oncol. 2021 Feb 24;14(1):35.

[2]. hillon S. Moxetumomab Pasudotox: First Global Approval. Drugs. 2018 Nov;78(16):1763-1767.

[3]. Kinjyo I, et al. Characterization of the anti-CD22 targeted therapy, moxetumomab pasudotox, for B-cell precursor acute lymphoblastic leukemia. Pediatr Blood Cancer. 2017 Nov;64(11):10.1002/pbc.26604.

[4]. Müller F, et al. 5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox. Proc Natl

Acad Sci U S A. 2018 Feb 20;115(8):E1867-E1875.

[5]. Ksenia Matlawska-Wasowska, et al. Variability In Precursor B ALL Killing With Moxetumomab Pasudotox (CAT-8015) Linked To Differential Binding and Endocytic Trafficking. Blood (2013) 122 (21): 5022.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA